Therapeutic Areas Regenerative Medicine / Gene Therapy

Regenerative Medicine / Gene Therapy

With more the 50% of CTI's active prospective studies involving regenerative medicine, including contributing to the development program of several of the world's first approved gene therapy products, the company is a leader in the field. Our work in regenerative medicine reaches across 400 sites in 30 countries around the world.

Terry Peltier-Siemers RN, BS
Principal Clinical Research Associate
With nearly 45 years of industry experience, including 20 years of oncology work, Terry has a vast background of therapeutic and drug development knowledge. Terry has interacted with hundreds of site personnel, educating them on changes in the industry, including regenerative and personalized medicine.

Peltier-SiemersT

We understand the specific challenges these projects present, including regulatory hurdles, complex logistics around biological sample collection, shipment, and implantation, as well as complicated site training requirements based on unique cell and gene technologies. Our experience includes both autologous and allogeneic stem cells as well as other cell/gene interventions. We work with innovators, key opinion leaders, cutting edge biotechnology/pharmaceutical companies, and investigators on our ongoing programs, as well as participate in industry groups such as the Alliance for Regenerative Medicine (ARM). We are committed to the advancement of important, life-changing therapies, and we support innovation by sponsoring and speaking at industry meetings such as Stem Cell on the Mesa, RegenMed Investor Day, and the Advanced Therapies Summit

Some of our adult and pediatric experience includes:

Specific areas

  • Acute lymphoblastic leukemia
  • Acute lymphoblastic lymphoma
  • Adenocarcinoma
  • Adenovirus
  • Advanced liver cancer
  • Allogeneic hematopoetic stem cell transplantation
  • B cell lymphoma
  • Beta hemoglobinopathies
  • BK virus
  • Beta-Thalassemia
  • Bronchopulmonary dysplasia
  • Childhood cerebral adrenoleukodystrophy
  • Choroideremia
  • Chronic kidney disease
  • Crohn's disease
  • Cytomegalovirus
  • Degenerative disc disease
  • End stage renal disease
  • Farber disease
  • Hematologic malignancy (AML, ALL, or MDS)
  • Hematopoietic stem cells
  • Kidney cell
  • Kidney transplant
  • Metabolic diseases
  • MPS I
  • MPS II
  • Non-hodgkin's lymphoma
  • Osteoarthritis
  • Peritoneal mesothelioma
  • Retinal dystrophy
  • Severe sickle cell disease
  • TK2 deficiency
  • Type I Diabetes Mellitus
  • Type II Diabetes

We offer our sponsors:

 

Request Information

Icon Contact Small Retina

CTI is ready to help with your next drug development project

Contact Us

CTI has Australian Government Gene Therapy Accreditation

Australia Gene Therapy Accreditation

 

CTI is an accredidated organization under the Gene Techonology Act 2000, given by the Office of the Gene Technology Regulator and Australian Governement Department of Health.

 

Learn More

CTI is a proud member of the Alliance for Regenerative Medicine!

ARM

Learn more